Literature DB >> 17409534

Genetic polymorphism of C452T (T127I) in human gamma-glutamyl hydrolase in a Japanese population.

Hideki Hayashi1, Chihiro Fujimaki, Kazuyuki Inoue, Toshio Suzuki, Kunihiko Itoh.   

Abstract

We investigated the genotype distribution and allele frequency of C452T polymorphism of gamma-glutamyl hydrolase (GGH) gene, which causes the decreased enzymatic activity affecting the efficacy of methotrexate (MTX), in a Japanese population. The polymerase chain reaction-restriction fragment length polymorphism assay was applied to determine the genotype of C452T polymorphism in 269 Japanese healthy individuals. The genotype distribution was as follows: C/C, 89.2% (n=240); C/T, 10.4% (n=28); T/T, 0.4% (n=1). The frequency of C and T allele was 0.944 and 0.056, respectively. The obtained genotype distribution was well agreed with those expected by Hardy-Weinberg equilibrium. The genotype distribution and allele frequency in a Japanese population were found to be similar to those of African-Americans but significantly different from Caucasians. Although the frequency of variant T allele in a Japanese population is not so high as compared to Caucasians, determination of C452T polymorphism of GGH may be useful for monitoring of efficacy and side-effects of MTX for treatment of diseases such as rheumatoid arthritis or childhood acute leukemia. To our knowledge, this is the first report about the examination of C452T polymorphism of GGH in a Japanese population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409534     DOI: 10.1248/bpb.30.839

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  4 in total

1.  Pediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription database.

Authors:  Nanae Tanemura; Maika Asawa; Mayuko Kuroda; Tsuyoshi Sasaki; Yoshiaki Iwane; Hisashi Urushihara
Journal:  World J Pediatr       Date:  2018-11-30       Impact factor: 2.764

2.  Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.

Authors:  A Argiris; M V Karamouzis; R Smith; A Kotsakis; M K Gibson; S Y Lai; S Kim; B F Branstetter; Y Shuai; M Romkes; L Wang; J R Grandis; R L Ferris; J T Johnson; D E Heron
Journal:  Ann Oncol       Date:  2011-03-01       Impact factor: 32.976

3.  Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?

Authors:  Phuong Thu Vu Hoang; Jérôme Ambroise; Anne-France Dekairelle; Jean-François Durant; Valentina Butoescu; Vu Luan Dang Chi; Nghia Huynh; Tan Binh Nguyen; Annie Robert; Christiane Vermylen; Jean-Luc Gala
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

4.  Genetic polymorphisms of enzyme proteins and transporters related to methotrexate response and pharmacokinetics in a Japanese population.

Authors:  Masayuki Hashiguchi; Mikiko Shimizu; Jun Hakamata; Tomomi Tsuru; Takanori Tanaka; Midori Suzaki; Kumika Miyawaki; Takeshi Chiyoda; Osamu Takeuchi; Jiro Hiratsuka; Shin Irie; Junya Maruyama; Mayumi Mochizuki
Journal:  J Pharm Health Care Sci       Date:  2016-12-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.